Skip Navigation

European Heart Journal 1984 5(8):675-683;
Copyright © 1984 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by HALINEN, M. O.
Right arrow Articles by REHNBERG, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HALINEN, M. O.
Right arrow Articles by REHNBERG, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1984 The European Society of Cardiology

Antiarrhythmic efficacy of combined intravenous and oral mexiletine in acute myocardial infarction. A double blind placebo-controlled study

M. O. HALINEN, P. J. PENTIKÄINEN*, M. J. HELIN and S. REHNBERG

Department of Medicine, University of Kuopio SF-70210 Kuopio 21, Finland

Received 1 November 1983; revised 14 April 1984; .

Abstract

The antiarrhythmic efficacy of mexiletine in acute myocardial infarction (AMI) was studied in 99 patients randomized to mexiletine or placebo treatment. The loading dose was 250 mg i.v. and 400 mg orally followed by 200 mg orally 2 h later, and thereafter 200 mg t.i.d. up to 42 h. Arrhythmias occurring during 48 h were analysed from continuous electrocardiographic recordings.

AMI was verified in 35 of 50 mexiletine patients and in 38 of 49 placebo patients. No deaths or instances of ventricular fibrillation occurred in the AMI patients. The number of patients who had any event of accelerated idioventricular rhythm (AIVR; P<0.05), runs of ventricular premature beats (VPBs; P<0.01), ventricular tachycardia (P<0.01) and Ron T beats (P<0.05) was smaller in the mexiletine group than in the placebo group. The number of all VPBs (P<0.05), hours with occurrence of AIVR (P<0.05), runs (P<0.01) and Ron T beats (P<0.05) was smaller in the mexiletine than in the placebo group.

Serum levels of mexiletine tended to be low throughout the study. The half-life of the elimination was 13.7±7.2 h (means±S.D.). Adverse effects were infrequent, and the treatment was well-tolerated.

Combined iv. and oral mexiletine prophylaxis significantly suppressed repetitive ventricular tachyarrhythmias and RonT beats. However, no clinical benefit from mexiletine treatment could be shown in a coronary care unit with a low frequency of primary ventricular fibrillation.

Key Words: Acute myocardial infarction • ventricular arrhythmias • mexiletine • continuous ECG recording • antiarrhythmic agents


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.